[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537536":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":54,"collaborators":57,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":10,"eligibilityCriteria":88,"healthyVolunteers":85,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":10,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"real-world study (RWS)-Chemotherapy",null,[12],"Drug: physician's choice of chemotherapy",{"label":14,"type":10,"description":10,"interventionNames":15},"RWS-ICI",[16],"Drug: immune checkpoint inhibitor based therapy",[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","physician's choice of chemotherapy","physician's choice of chemotherapy for relapsed\u002Frefractory ovarian clear cell carcinoma",[9],{"type":19,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"immune checkpoint inhibitor based therapy","immune checkpoint inhibitor based therapy for relapsed\u002Frefractory ovarian clear cell carcinoma",[14],[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Qinglei Gao, PhD","CONTACT","+86 13871127473","qingleigao@hotmail.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","430030","China","CN",{"type":43,"coordinates":44},"Point",[45,46],114.26667,30.58333,{"lat":46,"lon":45},[49,52],{"name":50,"role":30,"phone":51,"phoneExt":10,"email":32},"Qinglei Gao, PhD, MD","+86-13871127473",{"name":50,"role":53,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Qinglei Gao","Prof.",[58,60,63,65,67,69,71,73,75,77,79,81],{"name":59,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":61,"class":62},"Henan Cancer Hospital","OTHER_GOV",{"name":64,"class":6},"Qilu Hospital of Shandong University",{"name":66,"class":6},"Hubei Cancer Hospital",{"name":68,"class":6},"Anhui Provincial Cancer Hospital",{"name":70,"class":6},"Peking University Cancer Hospital & Institute",{"name":72,"class":6},"Hunan Province Tumor Hospital",{"name":74,"class":6},"First Affiliated Hospital of Suzhou Medical College",{"name":76,"class":6},"Shandong Tumor Hospital",{"name":78,"class":6},"Chongqing University Cancer Hospital",{"name":80,"class":6},"First Affiliated Hospital of Zhongshan Medical University",{"name":82,"class":6},"Peking University Shenzhen Hospital","100537536","a-comparative-study-of-the-treatment-of-real-world-patients-with-clear-cell-carcinoma-of-the-ovary-100537536",false,"NCT06279104","A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary","Inclusion Criteria:\n\n1. Female patients with age ≥ 18 years old and ≤ 75 years old.\n2. There must be a histological diagnosis of ovarian clear cell carcinoma.\n3. Patients with recurrent or persistent ovarian clear cell carcinoma must have at least one-line pretreated platinum-containing chemotherapy.\n4. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.\n5. Expected survival time ≥ 12 weeks.\n\nExclusion Criteria:\n\n1.Histological evidence of non-ovarian clear cell carcinoma.","FEMALE","18 Years","75 Years",{"count":93,"type":94},150,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ICI)-based therapy in patients with relapsed\u002Frefractory ovarian clear cell carcinoma (OCCC), and compare the treatment response with the phase II, single-arm clinical trial INOVA to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab. The main questions it aims to answer are:\n\n* What is the efficacy of physician's choice of chemotherapy in relapsed\u002Frefractory OCCC patients in the real world?\n* Is ICI-based therapy more effective than physician's choice of chemotherapy in real-world for relapsed\u002Frefractory OCCC patients?\n* Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in Recurrent\u002FPersistent Ovarian Clear Cell Carcinoma (INOVA) trial more effective than physician's choice of chemotherapy?\n\nParticipants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (EHR)-derived data.",[98],"Ovarian Clear Cell Carcinoma",[100,101,102],"Ovarian clear cell carcinoma","real world study","immune checkpoint inhibitor","2024-08-11",{"date":105,"type":106},"2024-08-13","ACTUAL",{"date":108,"type":106},"2023-03-01",{"date":110,"type":94},"2025-05-01",{"name":5,"class":6},1]